Publications

Risk of Injection-Site Abscess among Infants Receiving a Preservative-Free, Two-Dose Vial Formulation of Pneumococcal Conjugate Vaccine in Kenya.

Burton, DC; Bigogo, GM; Audi, AO; Williamson, J; Munge, K; Wafula, J; Ouma, D; Khagayi, S; Mugoya, I; Mburu, J; Muema, S; Bauni, E; Bwanaali, T; Feikin, DR; Ochieng, PM; Mogeni, OD; Otieno, GA; Olack, B; Kamau, T; Van Dyke, MK; Chen, R; Farrington, P; Montgomery, JM; Breiman, RF; SCOTT, JA G; ... Laserson, KF.

2015

PloS one, (2015).10 10 10.1371/journal.pone.0141896.

Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis.

Diop, A; Atherly, D; Faye, A; Lamine Sall, F; CLARK, AD; Nadiel, L; Yade, B; Ndiaye, M; Fafa Cissé, M; Ba, M;

2015

Vaccine, (2015).33 Sup S1 10.1016/j.vaccine.2014.12.065.

Increased disease due to Haemophilus influenzae type b: population-based surveillance in eastern Gambia, 2008-2013.

MACKENZIE, GA; IKUMAPAYI, UN A; SCOTT, S; Idoko, O; ODUTOLA, A; Ndiaye, M; Sahito, SM; Osuorah, CD; Manjang, A; JARJU, S; BOJANG, A; ROCA, A; Secka, O; Zaman, A; Ceesay, L; Lowe-Jallow, Y; Sambou, S; JASSEH, M; ANTONIO, M; GREENWOOD, B; KAMPMANN, B; MULHOLLAND, K; Corrah, T; Howie, SR C;

2015

The Pediatric infectious disease journal, (2015).34 5 10.1097/INF.0000000000000645.

A systematic review of the social and economic burden of influenza in low- and middle-income countries.

De Francisco Shapovalova, N; Donadel, M; JIT, M; Hutubessy, R;

2015

Vaccine, (2015).33 48 10.1016/j.vaccine.2015.10.066.

A review of typhoid fever transmission dynamic models and economic evaluations of vaccination.

WATSON, CH; EDMUNDS, WJ;

2015

Vaccine, (2015).33 Sup Suppl 10.1016/j.vaccine.2015.04.013.

Temporal changes in nasopharyngeal carriage of Streptococcus pneumoniae serotype 1 genotypes in healthy Gambians before and after the 7-valent pneumococcal conjugate vaccine.

Ebruke, C; ROCA, A; Egere, U; Darboe, O; Hill, PC; GREENWOOD, B; WREN, BW; Adegbola, RA; ANTONIO, M;

2015

PeerJ, (2015).3 3 10.7717/peerj.903.

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.

Neafsey, DE; Juraska, M; Bedford, T; Benkeser, D; Valim, C; Griggs, A; Lievens, M; Abdulla, S; Adjei, S; Agbenyega, T; Agnandji, ST; Aide, P; Anderson, S; Ansong, D; Aponte, JJ; ASANTE, KP; Bejon, P; Birkett, AJ; Bruls, M; Connolly, KM; D'ALESSANDRO, U; Dobaño, C; Gesase, S; GREENWOOD, B; Grimsby, J; ... Wirth, DF.

2015

The New England journal of medicine, (2015).373 21 10.1056/NEJMoa1505819.

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.

RTS,S Clinical Trials Partnership,;

2015

Lancet, (2015).386 9988 10.1016/S0140-6736(15)60721-8.

Sample size determination for estimating antibody seroconversion rate under stable malaria transmission intensity.

Sepúlveda, N; DRAKELEY, C;

2015

Malaria journal, (2015).14 1 10.1186/s12936-015-0661-z.

Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community.

Ultsch, B; Damm, O; Beutels, P; Bilcke, J; Brüggenjürgen, B; Gerber-Grote, A; Greiner, W; Hanquet, G; Hutubessy, R; JIT, M; Knol, M; Von Kries, R; Kuhlmann, A; Levy-Bruhl, D; Perleth, M; Postma, M; Salo, H; Siebert, U; Wasem, J; Wichmann, O;

2015

PharmacoEconomics, (2015).34 3 10.1007/s40273-015-0335-2.